Novel antifungal agents in clinical trials

Samantha E. Jacobs, Panagiotis Zagaliotis, Thomas J. Walsh

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


Invasive fungal diseases due to resistant yeasts and molds are an important and increasing public health threat, likely due to a growing population of immunosuppressed hosts, increases in antifungal resistance, and improvements in laboratory diagnostics. The significant morbidity and mortality associated with these pathogens bespeaks the urgent need for novel safe and effective therapeutics. This review highlights promising investigational antifungal agents in clinical phases of development: fosmanogepix, ibrexafungerp, rezafungin, encochleated amphotericin B, oteseconazole (VT-1161), VT-1598, PC945, and olorofim. We discuss three first-in-class members of three novel antifungal classes, as well as new agents within existing antifungal classes with improved safety and tolerability profiles due to enhanced pharmacokinetic and pharmacodynamic properties.

Original languageEnglish
Article number507
StatePublished - 2022


  • Antifungal Agents
  • Clinical trials
  • Novel treatments
  • Pharmacokinetic and pharmacodynamic


Dive into the research topics of 'Novel antifungal agents in clinical trials'. Together they form a unique fingerprint.

Cite this